Severe Acute Respiratory Syndrome

Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus, called SARS-associated coronavirus (SARS-CoV). SARS was first reported in Asia in February 2003. Over the next few months, the illness spread to more than two dozen countries in North America, South America, Europe, and Asia before the SARS global outbreak of 2003 was contained.
Severe Acute Respiratory Syndrome

SARS or Severe Acute Respiratory Syndrome is a viral respiratory illness caused by a coronavirus - the SARS associated coronavirus (SARS-CoV) - which can be life-threatening.

Read More

Overview

Latest Severe Acute Respiratory Syndrome News and Research

Supercarriers: Just 2% of SARS-CoV-2 positive people carry 90% of the virus

Supercarriers: Just 2% of SARS-CoV-2 positive people carry 90% of the virus

A look at how coronavirus disease (COVID-19) affects Parkinson's

A look at how coronavirus disease (COVID-19) affects Parkinson's

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

A magnetofluidic platform for SARS-CoV-2 variant and respiratory pathogen detection

A magnetofluidic platform for SARS-CoV-2 variant and respiratory pathogen detection

Three-way strategy employed by SARS-CoV-2 during infection

Three-way strategy employed by SARS-CoV-2 during infection

Dominance of South African SARS-CoV-2 variant in the US is unlikely but possible

Dominance of South African SARS-CoV-2 variant in the US is unlikely but possible

Antibodies generated by malaria cross-react with SARS-CoV-2

Antibodies generated by malaria cross-react with SARS-CoV-2

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

Phosphatidic acid is a key common substrate for hepatitis C and SARS-CoV-2 replication

Phosphatidic acid is a key common substrate for hepatitis C and SARS-CoV-2 replication

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

Study reports new monoclonal antibodies with broad neutralizing capabilities against betacoronaviruses (including SARS-CoV-2)

Study reports new monoclonal antibodies with broad neutralizing capabilities against betacoronaviruses (including SARS-CoV-2)

Black fungus complicates India's COVID pandemic

Black fungus complicates India's COVID pandemic

Comprehensive blood atlas of COVID-19 identifies hallmarks of disease severity

Comprehensive blood atlas of COVID-19 identifies hallmarks of disease severity

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

mRNA-based COVID-19 vaccines are effective against Indian SARS-CoV-2 variant, says study

mRNA-based COVID-19 vaccines are effective against Indian SARS-CoV-2 variant, says study

Case study examines prescriptions and healthcare use in non-hospitalized COVID-19 recoverers

Case study examines prescriptions and healthcare use in non-hospitalized COVID-19 recoverers

Long and short-range risk of airborne transmission of SARS-CoV-2

Long and short-range risk of airborne transmission of SARS-CoV-2

Study confirms rare blood clotting risk linked to ChAdOx1-S vaccine - benefits still outweigh risks

Study confirms rare blood clotting risk linked to ChAdOx1-S vaccine - benefits still outweigh risks

Spread of minority SARS-CoV-2 variants in New York City

Spread of minority SARS-CoV-2 variants in New York City